Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, CorMedix Inc (NASDAQ: CRMD) closed at $13.58 down -2.58% from its previous closing price of $13.94. In other words, the price has decreased by -$2.58 from its previous closing price. On the day, 1.31 million shares were traded. CRMD stock price reached its highest trading level at $14.11 during the session, while it also had its lowest trading level at $13.41.
Ratios:
For a deeper understanding of CorMedix Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.99 and its Current Ratio is at 4.21. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on March 07, 2025, initiated with a Outperform rating and assigned the stock a target price of $18.
On January 13, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $15.
On August 26, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $13.Rodman & Renshaw initiated its Buy rating on August 26, 2024, with a $13 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 31 ’24 when Mistry Erin bought 1,500 shares for $9.99 per share. The transaction valued at 14,985 led to the insider holds 52,011 shares of the business.
Hurlburt Elizabeth sold 140,027 shares of CRMD for $1,565,670 on Nov 14 ’24. The EVP now owns 45,397 shares after completing the transaction at $11.18 per share. On Nov 14 ’24, another insider, Hurlburt Elizabeth, who serves as the Officer of the company, bought 140,027 shares for $11.12 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 921059456 and an Enterprise Value of 844032640. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 60.25, and their Forward P/E ratio for the next fiscal year is 9.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.16 while its Price-to-Book (P/B) ratio in mrq is 8.00. Its current Enterprise Value per Revenue stands at 10.224 whereas that against EBITDA is 56.559.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.61, which has changed by 2.0654628 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $15.38, while it has fallen to a 52-week low of $3.61. The 50-Day Moving Average of the stock is 22.70%, while the 200-Day Moving Average is calculated to be 36.57%.
Shares Statistics:
For the past three months, CRMD has traded an average of 2.01M shares per day and 1791880 over the past ten days. A total of 67.71M shares are outstanding, with a floating share count of 65.96M. Insiders hold about 2.75% of the company’s shares, while institutions hold 34.73% stake in the company. Shares short for CRMD as of 1748563200 were 8533637 with a Short Ratio of 4.24, compared to 1745971200 on 8043655. Therefore, it implies a Short% of Shares Outstanding of 8533637 and a Short% of Float of 12.73.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
